Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $748000.0.

  • Relay Therapeutics' Depreciation and Depletion fell 4528.16% to $748000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 2203.45%. This contributed to the annual value of $5.5 million for FY2024, which is 370.09% up from last year.
  • Per Relay Therapeutics' latest filing, its Depreciation and Depletion stood at $748000.0 for Q3 2025, which was down 4528.16% from $1.0 million recorded in Q2 2025.
  • Relay Therapeutics' 5-year Depreciation and Depletion high stood at $1.4 million for Q1 2024, and its period low was $748000.0 during Q3 2025.
  • Moreover, its 5-year median value for Depreciation and Depletion was $1.2 million (2022), whereas its average is $1.1 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first soared by 3953.97% in 2023, then crashed by 4528.16% in 2025.
  • Relay Therapeutics' Depreciation and Depletion (Quarter) stood at $1.0 million in 2021, then rose by 12.77% to $1.2 million in 2022, then rose by 17.92% to $1.4 million in 2023, then decreased by 2.98% to $1.3 million in 2024, then crashed by 43.93% to $748000.0 in 2025.
  • Its last three reported values are $748000.0 in Q3 2025, $1.0 million for Q2 2025, and $1.2 million during Q1 2025.